UNSPSC 51143214: Nicotine bitartrate

This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.2C4H6O6.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7M676M8YV, chemically known as pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:2) (9ci) but more generally known as nicotine bitartrate, which bears US NIH Compound Identifier 6174. Most nations, for tariff and trade purposes, schedule nicotine bitartrate under HS 29399990 and SITC 54149.

As of Q4 2014, NICOTINE BITARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC[C@H]1C2CCCNC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.O.O.

UNSPSC 51143214 Nicotine bitartrate is a Commodity code with minimal recent state and local procurement activity aligned to its nominal scope. The two recent opportunities tagged to this code involve naloxone procurement (Seminole County, Florida) and a Texas Health and Human Services Commission RFI on direct-to-manufacturer pharmacy programs — neither directly concerns nicotine bitartrate supply. The Seminole County solicitation (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives with quarterly deliveries to Sanford, Florida. The Texas HHS RFI (HHS0017013, posted April 3, 2026) gathers vendor capability information on direct-to-manufacturer prescription fulfillment without a formal competitive timeline or budget. Neither opportunity reflects actual demand for nicotine bitartrate itself.

Recent state and local solicitations under this code do not support a meaningful characterization of issuing-body mix, geographic concentration, or current market activity for nicotine bitartrate. The posted opportunities appear to be mislabeled against the code's actual commodity scope and do not indicate active procurement of nicotine products by state or local health, addiction-treatment, or regulatory agencies at this time. Firms pursuing contracts under this code should verify that opportunities explicitly name nicotine bitartrate or nicotine-replacement products in their scope before investing in pursuit.